Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 119

1.

The development of a predictive model to estimate cardiotoxic risk for patients with metastatic breast cancer receiving anthracyclines.

Dranitsaris G, Rayson D, Vincent M, Chang J, Gelmon K, Sandor D, Reardon G.

Breast Cancer Res Treat. 2008 Feb;107(3):443-50. Epub 2007 Nov 3.

PMID:
17978870
2.

Identifying patients at high risk for neutropenic complications during chemotherapy for metastatic breast cancer with doxorubicin or pegylated liposomal doxorubicin: the development of a prediction model.

Dranitsaris G, Rayson D, Vincent M, Chang J, Gelmon K, Sandor D, Reardon G.

Am J Clin Oncol. 2008 Aug;31(4):369-74. doi: 10.1097/COC.0b013e318165c01d.

PMID:
18845996
3.

Cardiac safety profile of prolonged (>or=6 cycles) pegylated liposomal doxorubicin administration in patients with gynecologic malignancies.

Uyar D, Kulp B, Peterson G, Zanotti K, Markman M, Belinson J.

Gynecol Oncol. 2004 Jul;94(1):147-51.

PMID:
15262133
4.

Chemotherapy and cardiotoxicity in older breast cancer patients: a population-based study.

Doyle JJ, Neugut AI, Jacobson JS, Grann VR, Hershman DL.

J Clin Oncol. 2005 Dec 1;23(34):8597-605.

PMID:
16314622
5.

New insight into epirubicin cardiac toxicity: competing risks analysis of 1097 breast cancer patients.

Ryberg M, Nielsen D, Cortese G, Nielsen G, Skovsgaard T, Andersen PK.

J Natl Cancer Inst. 2008 Aug 6;100(15):1058-67. doi: 10.1093/jnci/djn206. Epub 2008 Jul 29.

PMID:
18664656
6.

Metronomic administration of pegylated liposomal-doxorubicin in extensively pre-treated metastatic breast cancer patients: a mono-institutional case-series report.

Munzone E, Di Pietro A, Goldhirsch A, Minchella I, Verri E, Cossu Rocca M, Marenghi C, Curigliano G, Radice D, Adamoli L, Nolè F.

Breast. 2010 Feb;19(1):33-7. doi: 10.1016/j.breast.2009.10.003. Epub 2009 Nov 1.

PMID:
19884008
7.

Cardiac toxicity associated with anthracycline-containing chemotherapy in older women with breast cancer.

Du XL, Xia R, Liu CC, Cormier JN, Xing Y, Hardy D, Chan W, Burau K.

Cancer. 2009 Nov 15;115(22):5296-308. doi: 10.1002/cncr.24621. Erratum in: Cancer. 2009 Dec 15;115(24):5849-51.

8.

Phase II multicenter trial of anthracycline rechallenge with pegylated liposomal doxorubicin plus cyclophosphamide for first-line therapy of metastatic breast cancer previously treated with adjuvant anthracyclines.

Trudeau ME, Clemons MJ, Provencher L, Panasci L, Yelle L, Rayson D, Latreille J, Vandenberg T, Goel R, Zibdawi L, Rahim Y, Pouliot JF.

J Clin Oncol. 2009 Dec 10;27(35):5906-10. doi: 10.1200/JCO.2009.22.7504. Epub 2009 Oct 26.

PMID:
19858391
9.

Pegylated liposomal doxorubicin in elderly patients with metastatic breast cancer.

Minisini AM, Andreetta C, Fasola G, Puglisi F.

Expert Rev Anticancer Ther. 2008 Mar;8(3):331-42. doi: 10.1586/14737140.8.3.331. Review.

PMID:
18366282
10.

Cardioprotective effect of dexrazoxane in patients with breast cancer treated with anthracyclines in adjuvant setting: a 10-year single institution experience.

Testore F, Milanese S, Ceste M, de Conciliis E, Parello G, Lanfranco C, Manfredi R, Ferrero G, Simoni C, Miglietta L, Ferro S, Giaretto L, Bosso G.

Am J Cardiovasc Drugs. 2008;8(4):257-63.

PMID:
18690759
11.

Doxorubicin, cardiac risk factors, and cardiac toxicity in elderly patients with diffuse B-cell non-Hodgkin's lymphoma.

Hershman DL, McBride RB, Eisenberger A, Tsai WY, Grann VR, Jacobson JS.

J Clin Oncol. 2008 Jul 1;26(19):3159-65. doi: 10.1200/JCO.2007.14.1242.

PMID:
18591554
12.

Skin toxicity associated with pegylated liposomal doxorubicin (40 mg/m2) in the treatment of gynecologic cancers.

Kim RJ, Peterson G, Kulp B, Zanotti KM, Markman M.

Gynecol Oncol. 2005 May;97(2):374-8.

PMID:
15863132
13.

Biweekly pegylated liposomal doxorubicin as second-line treatment in patients with relapsed ovarian cancer after failure of platinum and paclitaxel: results from a multi-center phase II study of the NOGGO.

Oskay-Oezcelik G, Koensgen D, Hindenburg HJ, Klare P, Schmalfeldt B, Lichtenegger W, Chekerov R, Al-Batran SE, Neumann U, Sehouli J; Ovarian Cancer Study Group of the North-Eastern Germany Society of Gynecological Oncology (NOGGO)..

Anticancer Res. 2008 Mar-Apr;28(2B):1329-34.

14.

Cardiac safety of liposomal anthracyclines.

Ewer MS, Martin FJ, Henderson C, Shapiro CL, Benjamin RS, Gabizon AA.

Semin Oncol. 2004 Dec;31(6 Suppl 13):161-81. Review.

PMID:
15717742
16.

Subclinical late cardiomyopathy after doxorubicin therapy for lymphoma in adults.

Hequet O, Le QH, Moullet I, Pauli E, Salles G, Espinouse D, Dumontet C, Thieblemont C, Arnaud P, Antal D, Bouafia F, Coiffier B.

J Clin Oncol. 2004 May 15;22(10):1864-71.

PMID:
15143078
17.

Cardiotoxic consequences of anthracycline-containing therapy in patients with breast cancer.

Jensen BV.

Semin Oncol. 2006 Jun;33(3 Suppl 8):S15-21. Review.

PMID:
16781285
18.

Multicenter phase II study of pegylated liposomal doxorubicin in combination with vinorelbine as first-line treatment in elderly patients with metastatic breast cancer.

Mlineritsch B, Schabel-Moser R, Andel J, Fridrik M, Moik M, Mayer P, Russ G, Rass C, Greil R; Arbeitsgemeinschaft medikamentöse Tumortherapie Study Group..

Onkologie. 2009 Feb;32(1-2):18-24. doi: 10.1159/000180915. Epub 2009 Jan 20.

PMID:
19209014
19.

Predisposing risk factors for palmar-plantar erythrodysesthesia when using liposomal doxorubicin to treat recurrent ovarian cancer.

Tanyi JL, Smith JA, Ramos L, Parker CL, Munsell MF, Wolf JK.

Gynecol Oncol. 2009 Aug;114(2):219-24. doi: 10.1016/j.ygyno.2009.04.007. Epub 2009 May 17.

PMID:
19446868
20.

Population pharmacokinetics and pharmacodynamics of doxorubicin and cyclophosphamide in breast cancer patients: a study by the EORTC-PAMM-NDDG.

Joerger M, Huitema AD, Richel DJ, Dittrich C, Pavlidis N, Briasoulis E, Vermorken JB, Strocchi E, Martoni A, Sorio R, Sleeboom HP, Izquierdo MA, Jodrell DI, Féty R, de Bruijn E, Hempel G, Karlsson M, Tranchand B, Schrijvers AH, Twelves C, Beijnen JH, Schellens JH; EORTC-PAMM-NDDG..

Clin Pharmacokinet. 2007;46(12):1051-68.

PMID:
18027989

Supplemental Content

Support Center